BR0015294A - Método para tratamento da diabetes - Google Patents

Método para tratamento da diabetes

Info

Publication number
BR0015294A
BR0015294A BR0015294-3A BR0015294A BR0015294A BR 0015294 A BR0015294 A BR 0015294A BR 0015294 A BR0015294 A BR 0015294A BR 0015294 A BR0015294 A BR 0015294A
Authority
BR
Brazil
Prior art keywords
diabetes
treating diabetes
employing
treating
treatment
Prior art date
Application number
BR0015294-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0015294A publication Critical patent/BR0015294A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0015294-3A 1999-11-03 2000-10-13 Método para tratamento da diabetes BR0015294A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
BR0015294A true BR0015294A (pt) 2003-07-15

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015294-3A BR0015294A (pt) 1999-11-03 2000-10-13 Método para tratamento da diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (cg-RX-API-DMAC7.html)
JP (1) JP5183844B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070089259A (cg-RX-API-DMAC7.html)
CN (1) CN1450902A (cg-RX-API-DMAC7.html)
AR (1) AR026356A1 (cg-RX-API-DMAC7.html)
AT (1) ATE390140T1 (cg-RX-API-DMAC7.html)
AU (1) AU780106B2 (cg-RX-API-DMAC7.html)
BR (1) BR0015294A (cg-RX-API-DMAC7.html)
CA (1) CA2389928C (cg-RX-API-DMAC7.html)
EE (1) EE05260B1 (cg-RX-API-DMAC7.html)
HU (1) HU229352B1 (cg-RX-API-DMAC7.html)
IL (1) IL149139A0 (cg-RX-API-DMAC7.html)
LT (1) LT5058B (cg-RX-API-DMAC7.html)
LV (1) LV12910B (cg-RX-API-DMAC7.html)
MX (1) MXPA02004282A (cg-RX-API-DMAC7.html)
NO (1) NO330026B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ518278A (cg-RX-API-DMAC7.html)
PL (1) PL199278B1 (cg-RX-API-DMAC7.html)
RU (1) RU2275915C2 (cg-RX-API-DMAC7.html)
SK (1) SK287810B6 (cg-RX-API-DMAC7.html)
TW (1) TWI280125B (cg-RX-API-DMAC7.html)
UY (1) UY26424A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001032157A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ,インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
TWI350751B (en) * 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
AU2005240122B2 (en) * 2004-05-03 2011-02-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
MX2010002695A (es) 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
NZ703128A (en) 2010-05-11 2016-04-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
JP6381914B2 (ja) * 2011-02-02 2018-08-29 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者における低血糖の予防
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
TR199903057T2 (xx) 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
DE69818444T2 (de) * 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
WO2001032157A2 (en) 2001-05-10
AR026356A1 (es) 2003-02-05
UY26424A1 (es) 2001-05-31
JP5183844B2 (ja) 2013-04-17
AU1082601A (en) 2001-05-14
NO330026B1 (no) 2011-02-07
WO2001032157A3 (en) 2002-01-24
NZ518278A (en) 2004-10-29
LT5058B (lt) 2003-09-25
SK287810B6 (sk) 2011-10-04
RU2275915C2 (ru) 2006-05-10
SK5002002A3 (en) 2004-05-04
NO20022087D0 (no) 2002-05-02
NO20022087L (no) 2002-06-24
MXPA02004282A (es) 2003-02-17
RU2002114820A (ru) 2004-03-10
PL364885A1 (en) 2004-12-27
TWI280125B (en) 2007-05-01
HU229352B1 (en) 2013-11-28
AU780106B2 (en) 2005-03-03
CA2389928A1 (en) 2001-05-10
KR20070089259A (ko) 2007-08-30
EE05260B1 (et) 2010-02-15
ATE390140T1 (de) 2008-04-15
HUP0300218A3 (en) 2006-02-28
EE200200242A (et) 2003-12-15
LT2002063A (en) 2003-06-25
HUP0300218A2 (hu) 2003-06-28
CN1450902A (zh) 2003-10-22
IL149139A0 (en) 2002-11-10
JP2003519621A (ja) 2003-06-24
EP1229918A2 (en) 2002-08-14
CA2389928C (en) 2010-03-23
EP1229918B1 (en) 2008-03-26
PL199278B1 (pl) 2008-09-30
LV12910B (en) 2003-05-20

Similar Documents

Publication Publication Date Title
TNSN00206A1 (en) Method for treating diabetes
UY26424A1 (es) Método para tratar la diabetes
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
SG149814A1 (en) Compositions and methods for treating diabetes
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
BR0317450A (pt) Fluidos de diálise biocompatìveis contendo icodextrinas
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9916279A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
DK403188A (da) Piperazinylpurin og fremgangsmaade til fremstilling deraf
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
BRPI0013924B8 (pt) soluções farmacêuticas de levosimendano
FI935693A7 (fi) Bifenyylin johdannaiset, niiden valmistus ja käyttö korkean verenpaineen ja sydäntautien hoitoon
BR9814075A (pt) Método de tratamento da doença de alzheimer
SE0102147D0 (sv) New methods
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
BRPI0413481A (pt) cascas de lêvedos para o tratamento ou a prevenção da hiperglicemia ou para a estabilização da glicemia
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
PT785787E (pt) Utilizacao de derivados de 1,5-benzodiazepina para o controlo de esvaziamento gastrico em doentes com diabetes mellitus nao-insulino dependentes
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 10(VIII) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.